15-type HPV Genotyping
15-type HPV Genotyping

[Product Name]

Human Papillomavirus (HPV) Nucleic Acid Typing Detection Kit 1.1

15-type HPV Genotyping CHE-HPV15-101

[Packing Specifications]

12 tests / box

[Applicable Models]

Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer

[Download Brochure]

15-type HPV GenotypingChenghui-Multi-Disc-15-Human-Papillomavirus-HPV-Nucleic-Acid-Typing-Detection-Kit-Brochure.pdf



No Data

Testing Process

No Data

Intended Use


This kit is a multiplex nucleic acid test intended for the qualitative detection and identification of Human Papillomavirus (HPV) types 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68 nucleic acid DNA in female cervical exfoliated cell samples.


Clinical Challenges


Persistent infection with high-risk Human Papillomavirus (HPV) is the primary cause of cervical cancer, the fourth most common cancer in women globally. Accurate HPV genotyping is critical for cervical cancer screening, risk stratification and standardized clinical management. Conventional diagnostic approaches face four core unmet needs:


Limited risk stratification capacity with suboptimal sensitivity of traditional screening

Cytology-based tests (e.g., Pap smear, TCT) have relatively low sensitivity and high false-negative rates, leading to missed diagnoses. Most routine HPV assays only distinguish high-risk from low-risk types without precise subtyping, making it impossible to stratify patients with high-carcinogenic genotypes such as HPV 16 and 18, which often results in over-treatment or insufficient clinical intervention.


Long centralized testing turnaround reduces patient follow-up compliance

Traditional HPV nucleic acid testing relies on centralized molecular laboratories, with complex workflows for sample transfer and batch processing. Reports typically take 3–7 days to issue, requiring multiple return visits for patients. This leads to high loss-to-follow-up rates and delays in necessary clinical intervention.


High operational barriers limit deployment in primary care and clinical departments

Conventional nucleic acid testing requires standardized PCR laboratories and certified technical personnel with complex pre-processing workflows. It cannot be easily deployed in gynecology outpatient departments, inpatient wards or primary care facilities, greatly limiting the accessibility of precise HPV genotyping.


High implementation costs constrain large-scale public health screening

Population-level cervical cancer screening requires processing large volumes of samples. Traditional reagents rely strictly on cold chain storage and transportation, and demand professional operation teams. These barriers restrict screening coverage in grassroots and remote areas, dragging down overall public health prevention efficiency.


Core Clinical Benefits


The Human Papillomavirus (HPV) Nucleic Acid Typing Detection Kit (15 targets), paired with the Multi-Disc fully automated nucleic acid analysis platform, directly addresses the above clinical and public health pain points:


15-type HPV GenotypingPrecise 15-genotype profiling to support evidence-based clinical decision-making

A single run achieves qualitative detection and genotyping of 15 high-risk HPV genotypes, covering all carcinogenic HPV subtypes recognized by the WHO, including the highest-risk HPV 16 and 18. It provides clear evidence for clinical risk stratification, colposcopy referral and post-treatment follow-up, optimizing the full cervical cancer care pathway.


Results in around 80 minutes to improve care efficiency and patient compliance

Total testing time is around 80 minutes, with only 1 minute of hands-on sample loading. Full genotyping reports are available on the same day, eliminating the need for repeated patient visits and improving follow-up compliance. It also supports rapid pre-admission screening for inpatients and stat testing in outpatient settings, enabling faster clinical care planning.


Low-barrier POCT deployment to expand diagnostic accessibility

Powered by the fully automated closed Multi-Disc platform, the assay requires no standardized molecular laboratory or specialized technical staff, and can be deployed directly in gynecology departments, physical examination centers and primary care facilities. It significantly shortens sample turnaround time (TAT), bringing precise HPV genotyping testing to more care settings.


Scalable performance to support public health screening programs

With balanced throughput and room-temperature-stable lyophilized reagents, the kit eliminates reliance on strict cold chains. It efficiently supports population-level cervical cancer screening programs, reduces implementation costs in grassroots settings, improves screening coverage, and advances early diagnosis and treatment of cervical cancer.


Core Product Advantages


Guideline-aligned 15 high-risk genotype panel design

The panel covers 15 globally recognized high-risk and probable high-risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68), fully consistent with international cervical cancer screening and management guidelines. It meets the needs of routine clinical screening, high-risk patient management and post-operative follow-up.


Fully automated closed sample-to-result workflow

Leveraging proprietary centrifugal microfluidic technology, the kit integrates two gold-standard workflows — silica membrane-based nucleic acid extraction and multiplex real-time qPCR — within a single enclosed disposable cartridge. Only 1 minute of manual pipetting is required, with no professional molecular operation expertise needed, delivering true "load-and-go" detection.

15-type HPV Genotyping


Balanced throughput for diverse clinical and public health scenarios

Compatible with the Multi-Disc (Model: CQ-0404) Fully Automated Nucleic Acid Analyzer, the platform supports parallel testing of 4 samples per run with full genotyping results available in around 80 minutes. It balances speed and batch processing capacity to fit gynecology stat testing, inpatient pre-admission screening and large-scale public health screening.


Lyophilized reagents for room-temperature storage and transport

With our self-developed PCR reagent lyophilization process, pre-embedded lyophilized reagent beads in the microfluidic chip enable room-temperature storage and transportation, eliminating cold chain reliance and greatly reducing storage and distribution costs for facilities of all sizes and remote screening sites.


Zero cross-contamination closed cartridge system

Each sample is processed in an individual sealed disposable cartridge, with amplification products never exposed to the external environment. This design fundamentally eliminates aerosol cross-contamination, reduces laboratory quality control burden, and ensures consistent, reliable genotyping results.


CE-compliant with clinically validated sample compatibility

The assay is fully validated for female cervical exfoliated cell samples. All 15 HPV genotyping targets are CE-marked, meeting regulatory requirements for clinical cervical cancer screening, patient management and public health prevention across global markets.